<DOC>
	<DOCNO>NCT01935856</DOCNO>
	<brief_summary>This study design evaluate safety , pharmacokinetics pharmacodynamics single multiple administration KHK7580 secondary hyperparathyroidism patient receive hemodialysis</brief_summary>
	<brief_title>Phase 1/2 Study KHK7580 Secondary Hyperparathyroidism Patients Receiving Hemodialysis</brief_title>
	<detailed_description />
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<criteria>Written inform consent Stable chronic renal disease patient receive hemodialysis 3 time weekly least 12 week prior screen intact PTH value ≥ 240 pg/mL screening Corrected serum calcium ≥ 8.4 mg/dL screen Patients primary hyperparathyroidism Patients receive cinacalcet within 2 week prior screen Patients change dose dose regimen active vitamin D/ analog , phosphate binder and/or calcium contain compound within 2 week prior screen Patients receive parathyroidectomy and/or parathyroid intervention Patients uncontrolled hypertension and/or diabetes Patients severe heart disorder Patients severe hepatic disease Patients take investigational drug clinical trial within 12 week prior screen Patients judge ineligible participate study investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>patient</keyword>
	<keyword>receive</keyword>
	<keyword>hemodialysis</keyword>
	<keyword>Secondary</keyword>
</DOC>